Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.
Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
Company Details
- Employees
- 29
- Address
- Opexa Therapeutics, Inc.,
- Phone
- (281) 272-9331
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- opexatherapeutics.com
- Keywords
- IRVINE.
- HQ
- The Woodlands, Texas
Opexa Therapeutics Questions
Opexa Therapeutics's helpline number is (281) 272-9331
Opexa Therapeutics's website is opexatherapeutics.com
Opexa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/opexa-therapeutics
Opexa Therapeutics has
29 employees.
View email and phone details for 29
employees at Opexa Therapeutics.
Opexa Therapeutics's industry is
Biotechnology Research
Opexa Therapeutics's top competitors are
Genexine, Inc.,
Vgxi,
Pharmabcine Inc.,
Biocardia, Inc.,
Triumvira Immunologics, Inc.,
Kbi Biopharma,
Mongoose Bio Inc.,
Carrigent,
Bellicum Pharmaceuticals, Inc.,
Opexa Llc.
Opexa Therapeutics's support email address is info@opexatherapeutics.com
Opexa Therapeutics's categories are Biotechnology Research
